PER-070-14已完成未知
A PHASE 3B/4 RANDOMIZED DOUBLE BLIND STUDY OF 5 MG OF TOFACITINIB WITH AND WITHOUT METHOTREXATE IN COMPARISON TOADALIMUMAB WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- PFIZER S.A.,
- 入组人数
- 17
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
- 性别
- All
入选标准
- •Have moderate to severe rheumatoid arthritis
- •On methotrexate but inadequately controlled
- •Subjects must not have active tuberculosis or an inadequately treated tuberculosis infection
- •Subjects must use contraception
排除标准
- •Subjects who have been previously treated with adalimumab or Tofacitinib
- •Subjects with any current malignancy or a history of malignancy, with the exception of adequately treated or excised non metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
- •Subjects with specific laboratory test abnormalities
- •Subjects with specific types of infections
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to assess a novel medicine in the treatment of patients with moderately to severely active rheumatoid arthritisModerately to severely active Rheumatoid ArthritisMedDRA version: 18.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2014-000358-13-BGPfizer Inc. 235 East 42nd Street, New York, NY 100171,080
进行中（未招募）
1 期
A PHASE 3b/4 RANDOMIZED DOUBLE BLIND STUDY OF 5 MG OF TOFACITINIB WITH AND WITHOUT METHOTREXATE IN COMPARISON TO ADALIMUMAB WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS - N/AModerately to severely active Rheumatoid ArthritisMedDRA version: 18.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2014-000358-13-HRPfizer Inc. 235 East 42nd Street, New York, NY 100171,146
进行中（未招募）
1 期
A clinical trial to assess a novel medicine in the treatment of patients with moderately to severely active rheumatoid arthritisModerately to severely active Rheumatoid ArthritisMedDRA version: 17.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2014-000358-13-ROPfizer Inc. 235 East 42nd Street, New York, NY 100171,146
进行中（未招募）
1 期
A clinical trial to assess a novel medicine in the treatment of patients with moderately to severely active rheumatoid arthritisModerately to severely active Rheumatoid ArthritisMedDRA version: 19.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2014-000358-13-PLPfizer Inc., 235 East 42nd Street, New York, NY 100171,080
进行中（未招募）
1 期
A clinical trial to assess a novel medicine in the treatment of patients with moderately to severely active rheumatoid arthritisModerately to severely active Rheumatoid ArthritisMedDRA version: 18.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2014-000358-13-GBPfizer Inc. 235 East 42nd Street, New York, NY 100171,080